Back

Discontinuation of oral anticoagulation and risk of worse clinical outcomes in atrial fibrillation patients: a report from the Murcia AF Project III

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: The atrial fibrillation anticoagulation puzzle: putting the pieces together Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jose Miguel Rivera-Caravaca

University of Murcia, Murcia (Spain)

7 More presentations in this session

Presentation thumbnail
Peridevice leak and device-related thrombus in the OPTION randomized trial
Doctor O. wazni (Cleveland, US)
Abstract Slides
Presentation thumbnail
Impact of anaemia on OAC prescription and adverse outcomes in patients with AF and chronic HF: an analysis form a real-world observational prospective study
Doctor M. Vitolo (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Impact of Clinical Complexity Features on the Risk of Major Bleeding and Subsequent Outcomes in Atrial Fibrillation Patients: A Multistate Model analysis from Two Large Observational Registries
Doctor D. Mei (Modena, IT)
Abstract Slides Video
Presentation thumbnail
Comparative in-hospital outcomes of acute ischemic stroke by preexisting atrial flutter or atrial fibrillation, stratified by CHADSVA score
Doctor A. Folman (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Timing of stroke risk reassessment in atrial fibrillation patients with CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study
Doctor M. Anjum (Baerum, NO)
Abstract Slides Video

Access the full session

Session thumbnail
The atrial fibrillation anticoagulation puzzle: putting the pieces together

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Outcomes with oral anticoagulation resumption or discontinuation after an anticoagulation-related event in patients with atrial fibrillation
thumbnail
Congress Presentation
Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death
thumbnail
Congress Presentation
Risk of death, thromboembolic events, and bleeding in elderly patients with Atrial Fibrillation and Clinical Complexity who are not taking oral anticoagulation.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources